Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events.Citation: Journal of the American College of Cardiology. 77(16):1977-1990, 2021 04 27.PMID: 33888247Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Antihypertensive Agents/ae [Adverse Effects] | *Blood Pressure/de [Drug Effects] | *Drug-Related Side Effects and Adverse Reactions/ep [Epidemiology] | *Hypertension/dt [Drug Therapy] | *Hypertension/ep [Epidemiology] | *Patient Selection | Aged | Antihypertensive Agents/ad [Administration & Dosage] | Blood Pressure/ph [Physiology] | Cardiovascular Diseases/di [Diagnosis] | Cardiovascular Diseases/ep [Epidemiology] | Cardiovascular Diseases/pc [Prevention & Control] | Drug-Related Side Effects and Adverse Reactions/di [Diagnosis] | Female | Follow-Up Studies | Humans | Hypertension/di [Diagnosis] | Male | Middle Aged | Risk AssessmentYear: 2021ISSN:
|Item type||Current library||Collection||Call number||Status||Date due||Barcode|
|Journal Article||MedStar Authors Catalog||Article||33888247||Available||33888247|
BACKGROUND: Intensive systolic blood pressure (SBP) treatment prevents cardiovascular disease (CVD) events in patients with high CVD risk on average, though benefits likely vary among patients.
CONCLUSIONS: SPRINT participants with higher baseline predicted CVD risk gained greater absolute benefit from intensive treatment. Participants with high predicted benefit were also most likely to experience treatment-related AEs, but AEs were generally mild and transient. Patients should be prioritized for intensive SBP treatment on the basis of higher predicted benefit. (Systolic Blood Pressure Intervention Trial [SPRINT]; NCT01206062). Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
METHODS: This was a secondary analysis of SPRINT (Systolic Blood Pressure Intervention Trial). Separate benefit outcomes were the first occurrence of: 1) a CVD composite of acute myocardial infarction or other acute coronary syndrome, stroke, heart failure, or CVD death; and 2) all-cause mortality. Treatment-related AEs of interest included hypotension, syncope, bradycardia, electrolyte abnormalities, injurious falls, and acute kidney injury. Modified elastic net Cox regression was used to predict absolute risk for each outcome and absolute risk differences on the basis of 36 baseline variables available at the point of care with intensive versus standard treatment.
OBJECTIVES: The aim of this study was to predict the magnitude of benefit (reduced CVD and all-cause mortality risk) along with adverse event (AE) risk from intensive versus standard SBP treatment.
RESULTS: Among 8,828 SPRINT participants (mean age 67.9 years, 35% women), 600 CVD composite events, 363 all-cause deaths, and 481 treatment-related AEs occurred over a median follow-up period of 3.26 years. Individual participant risks were predicted for the CVD composite (C index = 0.71), all-cause mortality (C index = 0.75), and treatment-related AEs (C index = 0.69). Higher baseline CVD risk was associated with greater benefit (i.e., larger absolute CVD risk reduction). Predicted CVD benefit and predicted increased treatment-related AE risk were correlated (Spearman correlation coefficient = -0.72), and 95% of participants who fell into the highest tertile of predicted benefit also had high or moderate predicted increases in treatment-related AE risk. Few were predicted as high benefit with low AE risk (1.8%) or low benefit with high AE risk (1.5%). Similar results were obtained for all-cause mortality.